Table 2.
Clinical and therapeutic features and outcomes of COVID-19 patients admitted to the Hospital at Home during the study period
| Clinical characteristics | |
| Symptoms, n (%) | |
| Fever | 50 (79.4) |
| Cough | 50 (79.4) |
| Dyspnea | 20 (31.7) |
| Hyposmia/anosmia | 8 (12.7) |
| Dysgeusia | 9 (14.3) |
| Gastrointestinal | 9 (14.3) |
| Length of symptoms until transfer in days, median (IQR) | 10 (7–16) |
| Use of oxygen supply, n (%) | 1 (1.6) |
| Blood test parameters at admission | |
| C Reactive Protein, median mg/dL (IQR) | 2.6 (1.0–4.9) |
| Procalcitonin, median ng/mL (IQR) | 0.03 (0.03–0.05) |
| Lactate dehydrogenase, median U/L (IQR) | 249 (191.5–299.8) |
| Lymphocytes per 106/L, median (IQR) | 1100 (900–1400) |
| D-dimer, median ng/mL (IQR) | 400 (300–575) |
| Ferritin, median ng/mL (IQR) | 262 (110–526) |
| AST, median U/L (IQR) | 31.5 (24.8–44) |
| ALT, median U/L (IQR) | 28 (22–53) |
| Bilirubin, median mg/dL (IQR) | 0.5 (0.4–0.6) |
| Alkaline phosphatase, median U/L (IQR) | 66.5 (51–82.8) |
| Gamma-glutamyl transpeptidase, median U/L (IQR) | 30 (20–55) |
| Creatinine, median mg/dL (IQR) | 0.79 (0.68–0.94) |
| Prothrombin time, % (IQR) | 90.8 (83.9–99.2) |
| Initial radiological findings | |
| No initial chest X-ray performed, n (%) | 8 (12.7) |
| Radiological pattern, n (%) | |
| Normal chest X-ray | 6 (9.5) |
| Unilateral interstitial infiltrates | 19 (19.2) |
| Unilateral spotted interstitial infiltrates | 2 (3.2) |
| Bilateral interstitial infiltrates | 22 (34.9) |
| Other | 6 (9.5) |
| Complications, n (%) | |
| Admission to ICU | 4 (6.3) |
| ARDS | 0 |
| Mechanical ventilation | |
| Non-invasive | 0 |
| Invasive | 1 (1.6) |
| Pulmonary emboli | 0 |
| Shock | 0 |
| Therapeutic features | |
| Received treatment for COVID-19, n (%) | 52 (82.5) |
| Lopinavir/ritonavir, n (%) | 39 (61.9) |
| Median days (IQR) | 7 (3.2–10) |
| Hydroxychloroquine, n (%) | 51 (81.0) |
| Median days (IQR) | 5 (5–7) |
| Azithromycin, n (%) | 38 (60.3) |
| Median days (IQR) | 5 (5–5) |
| Remdesivir, n (%) | 1 (1.6) |
| Tocilizumab | 5 (7.9) |
| Other antiviral agents, n (%) | 5 (7.9) |
| Received antimicrobials to cover a potential bacterial infection, n (%) | 11 (17.5) |
| Received glucocorticoids, n (%) | 0 |
| Outcomes | |
| Treatment discontinuation due to adverse events, n (%) | 12 (19) |
| Readmission to hospital during HaH, n (%) | 1 (1.6) |
| Days after transfer to HaH, median (IQR) | 5 (−) |
| New consultation after HaH discharge, n (%) | 3 (4.8) |
| Days after discharge, mean (IQR) | 4 (2–6) |
| Readmission to hospital after HaH discharge, n (%) | 2 (3.2) |
| Days after discharge, mean (IQR) | 3.5 (1–6) |
| Death, n (%) | 0 |
ALT aspartate aminotransferase, ALT alanine aminotransferase